Cargando…

EGFR-TKIs联合伽玛刀治疗EGFR突变的肺腺癌伴脑转移的预后分析

BACKGROUND AND OBJECTIVE: Advanced epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma had a high overall incidence of brain metastasis during the full course, and local brain radiotherapy combined with systemic targeted therapy may be a better strategy. This study aimed to identify t...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533187/
https://www.ncbi.nlm.nih.gov/pubmed/31109441
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.05.08
_version_ 1783421135631679488
collection PubMed
description BACKGROUND AND OBJECTIVE: Advanced epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma had a high overall incidence of brain metastasis during the full course, and local brain radiotherapy combined with systemic targeted therapy may be a better strategy. This study aimed to identify the prognostic factors of EGFR-mutant brain-metastatic lung adenocarcinoma patients who received EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in combination with gamma knife radiosurgery. METHODS: Retrospective analysis of EGFR-mutant lung adenocarcinoma patients with brain metastases which developed at initial diagnosis or during EGFR-TKIs treatment period were performed. Intracranial progression free survival (PFS) was statistically analyzed between different subgroups to find out the prognostic factors including gender, age, smoking history, extracranial metastasis, EGFR mutation type, size and number of intracranial lesions, carcino-embryonic antigen (CEA) level, lung-molGPA score and so on. RESULTS: A total of 74 EGFR-mutant brain-metastatic lung adenocarcinoma patients were enrolled in this study, with median intracranial PFS of 14.7 months. One-year intracranial-progression-free rate was 58.5%, and two-year rate was 22.2%. Univariate survival analysis showed that patients with lower CEA level at initial diagnosis (< 10 ng/L)(16.9 months vs 12.6 months, P=0.012) and smaller intracranial lesions (< 2 cm)(15.4 months vs 10.8 months, P=0.021) and higher lung-molGPA score (> 3)(15 months vs 12.6 months, P=0.041) were prone to have a superior intracranial PFS. Multivariate analysis showed that CEA≥10 ng/mL and intracranial lesion≥2 cm were the independent risk factors of intracranial PFS. CONCLUSION: EGFR-TKIs in combination with gamma knife radiosurgery was an efficient treatment option to control the cranial tumor lesion. CEA≥10 μg/L at initial diagnosis and intracranial lesion≥2 cm were the risk factors of EGFR-mutant brain-metastatic lung adenocarcinoma patients receiving EGFR-TKIs in combination with gamma knife radiosurgery.
format Online
Article
Text
id pubmed-6533187
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-65331872019-06-07 EGFR-TKIs联合伽玛刀治疗EGFR突变的肺腺癌伴脑转移的预后分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Advanced epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma had a high overall incidence of brain metastasis during the full course, and local brain radiotherapy combined with systemic targeted therapy may be a better strategy. This study aimed to identify the prognostic factors of EGFR-mutant brain-metastatic lung adenocarcinoma patients who received EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in combination with gamma knife radiosurgery. METHODS: Retrospective analysis of EGFR-mutant lung adenocarcinoma patients with brain metastases which developed at initial diagnosis or during EGFR-TKIs treatment period were performed. Intracranial progression free survival (PFS) was statistically analyzed between different subgroups to find out the prognostic factors including gender, age, smoking history, extracranial metastasis, EGFR mutation type, size and number of intracranial lesions, carcino-embryonic antigen (CEA) level, lung-molGPA score and so on. RESULTS: A total of 74 EGFR-mutant brain-metastatic lung adenocarcinoma patients were enrolled in this study, with median intracranial PFS of 14.7 months. One-year intracranial-progression-free rate was 58.5%, and two-year rate was 22.2%. Univariate survival analysis showed that patients with lower CEA level at initial diagnosis (< 10 ng/L)(16.9 months vs 12.6 months, P=0.012) and smaller intracranial lesions (< 2 cm)(15.4 months vs 10.8 months, P=0.021) and higher lung-molGPA score (> 3)(15 months vs 12.6 months, P=0.041) were prone to have a superior intracranial PFS. Multivariate analysis showed that CEA≥10 ng/mL and intracranial lesion≥2 cm were the independent risk factors of intracranial PFS. CONCLUSION: EGFR-TKIs in combination with gamma knife radiosurgery was an efficient treatment option to control the cranial tumor lesion. CEA≥10 μg/L at initial diagnosis and intracranial lesion≥2 cm were the risk factors of EGFR-mutant brain-metastatic lung adenocarcinoma patients receiving EGFR-TKIs in combination with gamma knife radiosurgery. 中国肺癌杂志编辑部 2019-05-20 /pmc/articles/PMC6533187/ /pubmed/31109441 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.05.08 Text en 版权所有©《中国肺癌杂志》编辑部2019 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
EGFR-TKIs联合伽玛刀治疗EGFR突变的肺腺癌伴脑转移的预后分析
title EGFR-TKIs联合伽玛刀治疗EGFR突变的肺腺癌伴脑转移的预后分析
title_full EGFR-TKIs联合伽玛刀治疗EGFR突变的肺腺癌伴脑转移的预后分析
title_fullStr EGFR-TKIs联合伽玛刀治疗EGFR突变的肺腺癌伴脑转移的预后分析
title_full_unstemmed EGFR-TKIs联合伽玛刀治疗EGFR突变的肺腺癌伴脑转移的预后分析
title_short EGFR-TKIs联合伽玛刀治疗EGFR突变的肺腺癌伴脑转移的预后分析
title_sort egfr-tkis联合伽玛刀治疗egfr突变的肺腺癌伴脑转移的预后分析
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533187/
https://www.ncbi.nlm.nih.gov/pubmed/31109441
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.05.08
work_keys_str_mv AT egfrtkisliánhéjiāmǎdāozhìliáoegfrtūbiàndefèixiànáibànnǎozhuǎnyídeyùhòufēnxī
AT egfrtkisliánhéjiāmǎdāozhìliáoegfrtūbiàndefèixiànáibànnǎozhuǎnyídeyùhòufēnxī
AT egfrtkisliánhéjiāmǎdāozhìliáoegfrtūbiàndefèixiànáibànnǎozhuǎnyídeyùhòufēnxī
AT egfrtkisliánhéjiāmǎdāozhìliáoegfrtūbiàndefèixiànáibànnǎozhuǎnyídeyùhòufēnxī
AT egfrtkisliánhéjiāmǎdāozhìliáoegfrtūbiàndefèixiànáibànnǎozhuǎnyídeyùhòufēnxī